Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa

被引:48
作者
Gupta, Ankur [1 ]
Wood, Robin [2 ]
Kaplan, Richard [2 ]
Bekker, Linda-Gail [2 ]
Lawn, Stephen D. [1 ,2 ]
机构
[1] London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, London WC1, England
[2] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa
来源
PLOS ONE | 2013年 / 8卷 / 02期
基金
英国惠康基金; 美国国家卫生研究院;
关键词
HIV-ASSOCIATED TUBERCULOSIS; IMMUNE RECONSTITUTION DISEASE; SUB-SAHARAN AFRICA; PULMONARY TUBERCULOSIS; TREATMENT PROGRAM; INFECTED PATIENTS; EARLY OUTCOMES; RURAL UGANDA; ADULTS; DETERMINANTS;
D O I
10.1371/journal.pone.0055824
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Patients with prevalent or incident tuberculosis (TB) in antiretroviral treatment (ART) programmes in sub-Saharan Africa have high mortality risk. However, published data are contradictory as to whether TB is a risk factor for mortality that is independent of CD4 cell counts and other patient characteristics. Methods/Findings: This observational ART cohort study was based in Cape Town, South Africa. Deaths from all causes were ascertained among patients receiving ART for up to 8 years. TB diagnoses and 4-monthly CD4 cell counts were recorded. Mortality rates were calculated and Poisson regression models were used to calculate incidence rate ratios (IRR) and identify risk factors for mortality. Of 1544 patients starting ART, 464 patients had prevalent TB at baseline and 424 developed incident TB during a median of 5.0 years follow-up. Most TB diagnoses (73.6%) were culture-confirmed. A total of 208 (13.5%) patients died during ART and mortality rates were 8.84 deaths/100 person-years during the first year of ART and decreased to 1.14 deaths/100 person-years after 5 years. In multivariate analyses adjusted for baseline and time-updated risk factors, both prevalent and incident TB were independent risk factors for mortality (IRR 1.7 [95% CI, 1.2-2.3] and 2.7 [95% CI, 1.9-3.8], respectively). Adjusted mortality risks were higher in the first 6 months of ART for those with prevalent TB at baseline (IRR 2.33; 95% CI, 1.5-3.5) and within the 6 months following diagnoses of incident TB (IRR 3.8; 95% CI, 2.6-5.7). Conclusions: Prevalent TB at baseline and incident TB during ART were strongly associated with increased mortality risk. This effect was time-dependent, suggesting that TB and mortality are likely to be causally related and that TB is not simply an epiphenomenon among highly immunocompromised patients. Strategies to rapidly diagnose, treat and prevent TB prior to and during ART urgently need to be implemented.
引用
收藏
页数:8
相关论文
共 47 条
  • [1] Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study
    Amuron, Barbara
    Levin, Jonathan
    Birunghi, Josephine
    Namara, Geoffrey
    Coutinho, Alex
    Grosskurth, Heiner
    Jaffar, Shabbar
    [J]. AIDS RESEARCH AND THERAPY, 2011, 8
  • [2] [Anonymous], 2002, Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach
  • [3] Loss to Follow-Up and Mortality Among HIV-Infected People Co-Infected With TB at ART Initiation in Durban, South Africa
    Bassett, Ingrid V.
    Chetty, Senica
    Wang, Bingxia
    Mazibuko, Matilda
    Giddy, Janet
    Lu, Zhigang
    Walensky, Rochelle P.
    Freedberg, Kenneth A.
    Losina, Elena
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 (01) : 25 - 30
  • [4] Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa
    Boulle, Andrew
    Van Cutsem, Gilles
    Hilderbrand, Katherine
    Cragg, Carol
    Abrahams, Musaed
    Mathee, Shaheed
    Ford, Nathan
    Knight, Louise
    Osler, Meg
    Myers, Jonny
    Goemaere, Eric
    Coetzee, David
    Maartens, Gary
    [J]. AIDS, 2010, 24 (04) : 563 - U1
  • [5] Adjusting Mortality for Loss to Follow-Up: Analysis of Five ART Programmes in Sub-Saharan Africa
    Brinkhof, Martin W. G.
    Spycher, Ben D.
    Yiannoutsos, Constantin
    Weigel, Ralf
    Wood, Robin
    Messou, Eugene
    Boulle, Andrew
    Egger, Matthias
    Sterne, Jonathan A. C.
    [J]. PLOS ONE, 2010, 5 (11):
  • [6] The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study
    Cohen, Ted
    Murray, Megan
    Wallengren, Kristina
    Alvarez, Gonzalo G.
    Samuel, Elizabeth Y.
    Wilson, Douglas
    [J]. PLOS MEDICINE, 2010, 7 (06)
  • [7] Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology
    Del Amo, J
    Malin, AS
    Pozniak, A
    De Cock, KM
    [J]. AIDS, 1999, 13 (10) : 1151 - 1158
  • [8] The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
    Golub, Jonathan E.
    Saraceni, Valeria
    Cavalcante, Solange C.
    Pacheco, Antonio G.
    Moulton, Lawrence H.
    King, Bonnie S.
    Efron, Anne
    Moore, Richard D.
    Chaisson, Richard E.
    Durovni, Betina
    [J]. AIDS, 2007, 21 (11) : 1441 - 1448
  • [9] Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community
    Gupta, Ankur
    Wood, Robin
    Kaplan, Richard
    Bekker, Linda-Gail
    Lawn, Stephen D.
    [J]. PLOS ONE, 2012, 7 (03):
  • [10] Tuberculosis 3 The HIV-associated tuberculosis epidemic-when will we act?
    Harries, Anthony D.
    Zachariah, Rony
    Corbett, Elizabeth L.
    Lawn, Stephen D.
    Santos-Filho, Ezio T.
    Chimzizi, Rhehab
    Harrington, Mark
    Maher, Dermot
    Williams, Brian G.
    De Cock, Kevin M.
    [J]. LANCET, 2010, 375 (9729) : 1906 - 1919